In April 2016, we entered into a license agreement with Takeda Pharmaceuticals International AG in which we were granted an exclusive, royalty-bearing license to develop and commercialize relugolix and MVT-602. With development and commercialization responsibilities shared across multiple territories, Myovant and Takeda plan to advance relugolix through clinical trials for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. Takeda is actively conducting two Phase 3 registration studies of relugolix in Japan for the treatment of uterine fibroids. 


About Takeda

Takeda Pharmaceutical Company Limited (TSE: 4502) is a global, R&D-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its research efforts on oncology, gastroenterology and central nervous system therapeutic areas. It also has specific development programs in specialty cardiovascular diseases as well as late-stage candidates for vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology, central nervous system and gastroenterology, as well as its presence in emerging markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. For more information, visit



About Roivant

Roivant Sciences is a unique biopharmaceutical company with world-class drug development experts working across multiple clinical and functional areas to complete the development of promising late-stage drug candidates with the potential to significantly improve the lives of patients and their families. Roivant delivers R&D solutions to its industry partners by helping them unlock value from their pipelines and to realize the full potential of their research by completing the product development cycle.

Roivant's pipeline spans multiple therapeutic areas through strategic alliances, collaborations and partnerships with academic institutions and pharmaceutical companies, including Takeda Pharmaceuticals, Eisai, Vertex Pharmaceuticals, GlaxoSmithKline, Arena Pharmaceuticals, Arbutus Biopharma, Duke University and Cincinnati Children's Hospital Medical Center. 

Additional information about Roivant Sciences is available through its website,